“Those are common molecular classifications that we now have therapies for,” Toboni said. Those drugs include Jemperli (dostarlimab-gxly), approved in August 2023 to be given in combination with ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its experimental drug outperformed Merck’s Keytruda, the world’s best-selling drug, in non-small ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...

(RTTNews) - Merck & Co Inc. (MRK) on Thursday said that Health Canada has granted approval of Keytruda as a monotherapy to treat patients with unresectable or metastatic microsatellite instability ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...

Recommended Reading A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology An experimental medicine from a small biotechnology company cut the risk of lung cancer ...

The story — and the transformative impact — of Bristol Myers Squibb’s Opdivo and Merck’s Keytruda are well known at this point. Yet the field has also been in a moment of commemoration ...

(RTTNews) - Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved its blockbuster cancer drug Keytruda for yet another indication. Keytruda in combination with antibody-drug ...

The company (MRK) said the approval is the first for Keytruda to treat MPM in the U.S. and is in combination with pemetrexed and platinum chemotherapy. MPM is a rare and aggressive malignancy ...